MELBOURNE, Australia and SAN FRANCISCO, USA, August 12, 2026
Alterity Therapeutics Limited announced that the U.S. Patent and Trademark Office (USPTO) has granted a new composition-of-matter patent covering ATH434, its lead investigational oral therapy for neurodegenerative diseases including Multiple System Atrophy (MSA) and potentially Parkinson’s disease. The newly granted patent protects a crystalline form of the ATH434 mesylate salt and related methods of treating neurological conditions, extending intellectual property protection for the candidate to at least 2045. The milestone strengthens Alterity’s patent portfolio as the company prepares to initiate Phase 3 trial activities in MSA by the end of 2026. The company said the new intellectual property could also support future development of ATH434 in Parkinson’s disease and other neurodegenerative disorders associated with iron dysregulation and abnormal protein aggregation.
New Composition-of-Matter Patent Strengthens ATH434
The newly granted U.S. patent, titled “Crystalline Form, and Process for its Production,” covers the composition of matter of a crystalline form of ATH434 mesylate as well as methods for using the compound to treat neurological conditions. According to Alterity, this specific form of ATH434 was used in its Phase 2 clinical trials in MSA and is planned for use in the company’s future Phase 3 study. Composition-of-matter protection is considered an important form of pharmaceutical intellectual property because it can provide broad protection around a drug substance itself rather than only a particular use or formulation. Alterity expects the patent to provide another layer of commercial protection alongside its existing intellectual property and regulatory designations. If ATH434 ultimately receives regulatory approval, the company expects the patent to be eligible for listing in the FDA’s Orange Book, subject to applicable requirements. The extended protection through at least 2045 could potentially increase the commercial value of ATH434 and support future partnership opportunities.
ATH434 Advances Toward Phase 3 Development in MSA
ATH434 is an oral investigational agent designed to address underlying disease mechanisms associated with neurodegeneration by reducing iron accumulation and inhibiting abnormal protein aggregation. Preclinical research has indicated that ATH434 can reduce α-synuclein pathology and support neuronal function by helping restore normal iron balance in the brain. Alterity has reported positive findings from a randomized, double-blind, placebo-controlled Phase 2 study in patients with MSA, including clinically meaningful efficacy signals, biomarker evidence of target engagement and a favorable safety profile. A separate open-label Phase 2 biomarker study in patients with more advanced MSA also generated positive findings. The company is now preparing for Phase 3 development, with trial activities targeted to begin by year-end 2026. ATH434 has received FDA Fast Track Designation and FDA and European Commission Orphan Drug Designations for MSA, although these regulatory designations do not guarantee approval or establish clinical efficacy…
Advertisement
Expanded Potential for Parkinson’s Disease
The strengthened intellectual property position could also support future development of ATH434 beyond Multiple System Atrophy, particularly in Parkinson’s disease, where abnormal α-synuclein accumulation and disrupted iron regulation have been implicated in disease pathology. Alterity believes the new patent provides the protection needed to consider investment and development opportunities in this larger neurodegenerative market. Parkinson’s disease affects nearly one million people in the United States and more than 10 million worldwide, while MSA remains a rare and rapidly progressive disorder with no approved disease-modifying treatment. Alterity’s immediate priority remains advancing ATH434 toward a pivotal Phase 3 MSA program, but the broader intellectual property estate could provide a foundation for additional indications if future clinical studies demonstrate therapeutic potential. The patent therefore represents a significant strategic milestone, but the ultimate commercial value of ATH434 will depend on successful Phase 3 results and subsequent regulatory approval.
Source:Alterity Therapeutics press release
